Stemcell Safarivet

Allogenic Mesenchymal Stem Cell Therapy for Treatment of Non-Regenerative Anemia in Dogs

Allogenic Mesenchymal Stem Cell Therapy for Treatment of Non-Regenerative Anemia (NRA) in Dogs

Steven Garner DVM DABVP
Chief of Staff
Safari Veterinary Care Centers
League City, Texas 77573

Introduction and background

The justification for the use of stem cell therapy to treat immune mediated anemias in dogs can be demonstrated by the successful use of similar therapies in human medicine. The bone marrow is the source of red blood cells, white blood cells and platelets. All these cells come from a cell called a hematopoietic stem cell. Or blood creating stem cell. These stem cells create the three lines of cells that form all three of the cellular blood components (white, red and platelets). Hematopoietic stem cells live within the central marrow of the bones on a loose spongy matrix. The matrix is composed of calcified bony spicules which house osteoblasts and osteoclasts (that build and remodel bone), fibroblasts, reticular cells, and adipose cells (that make up the bone marrow matrix) as well as another stem cell called bone marrow stromal cells(BMSC). These bone marrow stromal cells are stem cells and are essential in producing the chemical stimulus for the hematopoietic stem cells to divide and form the blood cells. So, there are two essential stem cells in the bone marrow, one that produces the blood cells (hematopoietic) and another that provides the chemical instructions for this production (BMSC).

The hematopoietic stem cell first produces daughter stem cells that become the “mothers” of the individual cell lines. The red cell line “mother” is called the erythroblast, the white cell line “mothers” are called the myeloblast, lymphoblast and monoblast and the platelet cell line “mother” is called the megakaryocyte. The erythroblast makes red blood cells and the others make the different white blood cell lines as described in the figure below.

Non-Regenerative Anemia
Immune-mediated hemolytic anemia (IMHA) is caused when antibodies are produced against the red blood cell antigens. This causes the red blood cell to be destroyed either within the blood stream or within the spleen. This red cell destruction results in anemia which should stimulate the bone marrow to produce more red blood cells. This regenerative response is measured by identifying baby red blood cells (reticulocytes) in the circulation. When there are not adequate numbers of red blood cells in the circulation it is called non-regenerative anemia (NRA). NRA occurs because the erythroblast has also been targeted in the immune attack. In some cases, the bone marrow failure is due to exhaustion of the erythroblast cells or lack of raw materials such as iron. In human medicine, a similar disease called aplastic anemia(AA) occurs where there is an immune attack on the hematopoietic stem cell itself so that all cell lines are affected and the person has low red blood cells, low white blood cells and low platelets as well. In these cases, human patients are usually given a bone marrow transplant which is really a hematopoietic stem cell transplant. This transplant must be given from a sibling donor or a suitable unrelated donor with matching tissue type. This may not be readily available, and the patient must be maintained with blood transfusions and antibiotics.

Recently it has been demonstrated that mesenchymal stem cells (MSC) from adipose tissue can support the hematopoietic matrix within the bone marrow (1). MSC transfusions have been shown to cure AA patients through the stimulation of the production of a new hematopoietic matrix.


Non-Regenerative Anemia (NRA), Aplastic Anemia (AA), Pure Red Cell Aplasia (PRA) and Immune Mediated Thrombocytopenia (ITP) are similar diseases affecting the production of red blood cells and platelets in the bone marrow. All these diseases respond incompletely to immunosuppressive medications. Allogenic Mesenchymal Stem Cell (MSC) therapy can be used to improve the chances of recovery from these diseases through three paths: immunomodulation, increased hematopoiesis and the promotion of immune tolerance (2) (3).

Non-Regenerative Anemia (NRA) is a clinical term that indicates the lack of appropriate production of red blood cells in the face of red blood cell loss or destruction. NRA is usually determined by the lack of the appropriate number of reticulocytes in the peripheral blood. NRA may be caused by reduced production of red blood cells by the bone marrow or by conditions that inhibit erythropoietin production by the kidneys or processing of iron and hemoglobin by the liver. In the case of immune mediated hemolytic anemia (IMHA) in dogs it is thought that the progenitor cells in the bone marrow which produce the red blood cells are attacked by the same immune reaction that attacks the peripheral red blood cells. This immune reaction is like the immune reaction that occurs in aplastic anemia (AA) in humans except the NRA is characterized only by low red blood cell production while with AA white blood cell production and platelet production are low as well.

AA is an autoimmune disease causing total or partial bone marrow destruction. AA is characterized by peripheral blood pancytopenia, which is the reduction in the number of red blood cells and white blood cells as well as platelets. In human medicine, the first line treatment options are hematopoietic stem cell transplant and/or immunosuppressive drug administration (2). In human patients that do not respond to these therapies, mesenchymal stem cells have been shown to improve the hematopoietic niche in refractory severe aplastic anemia.

Pure Red Cell Aplasia (PRA) is an infrequent hematologic complication from hematopoietic stem cell transplantation when the transplanted cells are mismatched with the recipient. Allogenic mesenchymal stem cells have also demonstrated efficacy in the treatment of refractory PRA in humans (4) (5).

Immune mediate thrombocytopenia (ITP) is characterized by immune-mediated destruction of normal platelets and suppression of platelet production that is associated with variable bleeding syndromes. The underlying immune dysregulation results in antiplatelet antibodies directed at the platelet and megakaryocyte surface glycoproteins. These antiplatelet antibodies develop secondary to a loss of tolerance to these surface-antigens of the platelets and megakaryocytes (6).The pathophysiologic mechanisms for the formation IMHA, AA, PRA as well as immune mediated thrombocytopenia (ITP) is complex and involves the production of autoantibodies against the surface membranes of the red blood cells, the platelets and the respective bone marrow precursor and stromal cells. The formation of these autoantibodies by B-Cells requires the interaction of T-cells with the B-cells. Animals with these diseases have been shown to have an imbalance in the number of Inflammatory T-Cells and Regulatory T-Cells (T-reg) (7). Allogenic MSC therapy has been shown in numerous clinical trials to increase the number of T-reg cells (3). T-Reg cells are responsible for immune tolerance. Immune tolerance is the process by which the immune system tolerates cells that may otherwise appear foreign through the release of numerous cytokines that affect the inflammatory T-cells, B-cells, macrophages, and dendritic cells. Immune tolerance is normal and is responsible for the body’s ability to tolerate for example: intestinal bacteria, the unborn fetus, the skin and mucous membrane surface bacteria as well as normal red blood cells and platelets 1 . Mesenchymal stem cells therefore augment the immunosuppressive drug therapies because they possess broad immunomodulatory properties, secreting several biological molecules that influence both the adaptive and innate immune responses (3) (8).

The bone marrow stroma is a key structural element that contains nonhematopoietic progenitor cells (mesenchymal stem cells) that interact by secreting regulatory molecules and cytokines that provide stimulus to the natural bone marrow microenvironment for hematopoiesis. Replacing these cells through IV infusion of allogenic mesenchymal stem cells provides a potential solution for the bone marrow suppression. Allogenic MSC’s are hypoimmunogenic, thus displaying low expression levels of human leucocyte antigen (HLA) class I, and no expression of HLA class II 2 (4).


Allogenic MSC are anti-inflammatory, immunomodulatory and regenerative. Intravenous infusion of these cells has been shown to be a safe way to decrease the antibody induced destruction of cells while increasing the production of red blood cells and platelets in humans and animals suffering from various types of immune mediated cell and bone marrow damage.

1 Red blood cells and platelets are not alive, do not have a nucleus and therefore do not have MCH antigens to tell the body’s immune system they are “self”. The immune system must therefore tolerate the presence of these cells. This immune tolerance is mediated by T-reg cells.

2 Human Leukocyte Antigen (HLA) is analogous to the canine Major Histocompatibility Complex (MHC).


  1. Adipose tissue-derived mesenchymal stem cells facilitate hematopoiesis in vitro and in vivo: advantages over bone marrow-derived mesenchymal stem cells. Norihiko Nakao, Takayuki Nakayama,Takashi Yahata, Yukari Muguruma,Shigeki Saito, Yasuhiko Miyata,Koji Yamamoto, and Tomoki Naoe. 2, Nagoya, Japan : American Society for Investigative Pathology, August 2010, The American Journal of Pathology, Vol. 177.
  2. Mesenchymal Stem Cell Benefits Observed in Bone Marrow Failure and Acquired Aplastic Anemia. Vivian Fonseca Gonzaga, Cristiane Valverde Wenceslau, Gustavo Sabino Lisboa, Eduardo Osório Frare, and Irina Kerkis. Sao Paulo : Hindawi, 12 03, 2017, Stem Cells International. 1687-966X.
  3. Effects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevance. Negi Neema, Griffin Matthew D. Galway,Ireland : John Wiley & Sons, Ltd, 01 29, 2020, Stem Cells Journals. 1066-5099.
  4. Allogeneic Bone Marrow‐Derived Mesenchymal Stromal Cells Expanded In Vitro for Treatment of Aplastic Anemia: A Multicenter Phase II Trial. Jiang, Yan Pang Hao‐Wen Xiao Hang Zhang Zeng‐Hui Liu Li Li Yang Gao Hong‐Bo Li Zu‐Jun. [ed.] Anthony Atala. 7, Guangzhou : John Wiley & Sons, Ltd, 05 15, 2017, Stem Cells Translational Medicine, Vol. 6, pp. 1569-1575. 2157-6564.
  5. Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation. Fang, B., Song, Y., Li, N. et al. September 04, 2009, Ann Hematol.
  6. Despotovic, Jenny M. Immune Hematology – Diagnosis and Management of Autoimmune Cytopenias. Houston : Springer, 2018.
  7. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell–depleting therapy with rituximab. Roberto Stasi, Nichola Cooper, Giovanni Del Poeta, Elisa Stipa, Maria Laura Evangelista, Elisabetta Abruzzese, Sergio Amadori. 4, Rome, Italy : AmericanSocietyofHematology, 2008, Blood, Vol. 112, pp. 1147-1150. 0006-4971.
  8. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. K. Le Blanc, L. Tammik, B. Sundberg, S. E. Haynesworth, and O. Ringden. 01, s.l. : John Wiley & Sons, Ltd, 2003, Scandinavian Journal of Immunology, Vol. 51, pp. 11-20. 0300-9475.